Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ajay Nooka

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Cancer|June 22, 2010
Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective studyJonathan L Kaufman, Ajay Nooka, Mark Vrana, et al.
Blood Advances|May 22, 2024
Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myelomaHeinz Ludwig, Nikhil C Munshi, Evangelos Terpos, et al.
Clinical Trials (London, England)|August 31, 2015
Description of the types and content of phase 1 clinical trial consent conversations in practiceLouisa Wall, Zachary Luke Farmer, Margaret White Webb, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 6, 2011
Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United StatesPareen J Shenoy, Neha Malik, Rajni Sinha, et al.
Cancer|October 11, 2018
Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whitesSarah Chehab, Chao Zhang, Elyse H Panjic, et al.
Cancer|November 8, 2014
Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patientsMeagan S Barbee, Ajay Nooka, Jonathan L Kaufman, et al.
Cancer|September 20, 2013
Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United StatesPareen J Shenoy, Neha Malik, Ajay Nooka, et al.
Cancer|June 28, 2007
Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrenceEdward H Lin, Manal Hassan, Yanan Li, et al.
Blood Cancer Journal|December 15, 2020
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myelomaYanyan Gu, Benjamin G Barwick, Mala Shanmugam, et al.
Oncotarget|April 7, 2016
BCL2-BH4 antagonist BDA-366 suppresses human myeloma growthJiusheng Deng, Dongkyoo Park, Mengchang Wang, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Cancer|June 22, 2010
Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective studyJonathan L Kaufman, Ajay Nooka, Mark Vrana, et al.
Blood Advances|May 22, 2024
Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myelomaHeinz Ludwig, Nikhil C Munshi, Evangelos Terpos, et al.
Clinical Trials (London, England)|August 31, 2015
Description of the types and content of phase 1 clinical trial consent conversations in practiceLouisa Wall, Zachary Luke Farmer, Margaret White Webb, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 6, 2011
Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United StatesPareen J Shenoy, Neha Malik, Rajni Sinha, et al.
Cancer|October 11, 2018
Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whitesSarah Chehab, Chao Zhang, Elyse H Panjic, et al.
Cancer|November 8, 2014
Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patientsMeagan S Barbee, Ajay Nooka, Jonathan L Kaufman, et al.
Cancer|September 20, 2013
Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United StatesPareen J Shenoy, Neha Malik, Ajay Nooka, et al.
Cancer|June 28, 2007
Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrenceEdward H Lin, Manal Hassan, Yanan Li, et al.
Blood Cancer Journal|December 15, 2020
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myelomaYanyan Gu, Benjamin G Barwick, Mala Shanmugam, et al.
Oncotarget|April 7, 2016
BCL2-BH4 antagonist BDA-366 suppresses human myeloma growthJiusheng Deng, Dongkyoo Park, Mengchang Wang, et al.
Pageof 5